MacroGenics, Inc. (MGNX)
NASDAQ: MGNX · Real-Time Price · USD
4.250
+0.090 (2.16%)
At close: May 15, 2026, 4:00 PM EDT
4.350
+0.100 (2.35%)
After-hours: May 15, 2026, 7:46 PM EDT
MacroGenics Revenue
MacroGenics had revenue of $20.78M in the quarter ending March 31, 2026, with 57.48% growth. This brings the company's revenue in the last twelve months to $157.08M, up 1.97% year-over-year. In the year 2025, MacroGenics had annual revenue of $149.50M, down -0.31%.
Revenue (ttm)
$157.08M
Revenue Growth
+1.97%
P/S Ratio
1.72
Revenue / Employee
$536,119
Employees
293
Market Cap
270.13M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 149.50M | -462.00K | -0.31% |
| Dec 31, 2024 | 149.96M | 91.21M | 155.26% |
| Dec 31, 2023 | 58.75M | -93.19M | -61.33% |
| Dec 31, 2022 | 151.94M | 74.49M | 96.19% |
| Dec 31, 2021 | 77.45M | -27.44M | -26.16% |
| Dec 31, 2020 | 104.88M | 40.70M | 63.40% |
| Dec 31, 2019 | 64.19M | 4.07M | 6.76% |
| Dec 31, 2018 | 60.12M | -97.62M | -61.89% |
| Dec 31, 2017 | 157.74M | 65.86M | 71.68% |
| Dec 31, 2016 | 91.88M | -8.97M | -8.90% |
| Dec 31, 2015 | 100.85M | 53.06M | 111.00% |
| Dec 31, 2014 | 47.80M | -10.24M | -17.64% |
| Dec 31, 2013 | 58.04M | -5.79M | -9.07% |
| Dec 31, 2012 | 63.83M | 6.62M | 11.57% |
| Dec 31, 2011 | 57.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Compugen | 72.76M |
| Editas Medicine | 38.69M |
| Zentalis Pharmaceuticals | 26.87M |
| Tonix Pharmaceuticals Holding | 17.56M |
| AC Immune | 4.62M |
| Silence Therapeutics | 839.00K |
| SAB Biotherapeutics | 114.70K |
MGNX News
- 2 days ago - MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum - GlobeNewsWire
- 3 days ago - MacroGenics reports Q1 EPS (58c), consensus (55c) - TheFly
- 3 days ago - MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation - GlobeNewsWire
- 5 days ago - MacroGenics to sell GMP manufacturing operations to Bora for $122.5M upfront - TheFly
- 5 days ago - MacroGenics trading resumes - TheFly
- 5 days ago - MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals - GlobeNewsWire
- 5 days ago - MacroGenics trading halted, news pending - TheFly
- 12 days ago - MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement - TheFly